Cargando…

Clinical value of laboratory indicators for predicting disease progression and death in patients with COVID-19: a retrospective cohort study

OBJECTIVES: As early prediction of severe illness and death for patients with coronavirus disease 2019 (COVID-19) is important, we aim to explore the clinical value of laboratory indicators in evaluating the progression and prognosis of patients with COVID-19. DESIGN: Retrospective cohort study. SET...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qian, Cheng, Jie, Shang, Jian, Wang, Ying, Wan, Jing, Yan, You-qin, Liu, Wen-bin, Zhang, Hai-Ping, Wang, Jian-ping, Wang, Xiao-yue, Li, Zi-ang, Lin, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488281/
https://www.ncbi.nlm.nih.gov/pubmed/34598979
http://dx.doi.org/10.1136/bmjopen-2020-043790
_version_ 1784578129286660096
author Wang, Qian
Cheng, Jie
Shang, Jian
Wang, Ying
Wan, Jing
Yan, You-qin
Liu, Wen-bin
Zhang, Hai-Ping
Wang, Jian-ping
Wang, Xiao-yue
Li, Zi-ang
Lin, Jun
author_facet Wang, Qian
Cheng, Jie
Shang, Jian
Wang, Ying
Wan, Jing
Yan, You-qin
Liu, Wen-bin
Zhang, Hai-Ping
Wang, Jian-ping
Wang, Xiao-yue
Li, Zi-ang
Lin, Jun
author_sort Wang, Qian
collection PubMed
description OBJECTIVES: As early prediction of severe illness and death for patients with coronavirus disease 2019 (COVID-19) is important, we aim to explore the clinical value of laboratory indicators in evaluating the progression and prognosis of patients with COVID-19. DESIGN: Retrospective cohort study. SETTING: Hospital-based study in China. PARTICIPANTS: Adult patients with COVID-19 from December 15, 2019 to March 15, 2020. END POINT: Disease severity and mortality. METHODS: Clinical data of 638 patients with COVID-19 were collected and compared between severe and non-severe groups. The predictive ability of laboratory indicators in disease progression and prognosis of COVID-19 was analysed using the receiver operating characteristic curve. The survival differences of COVID-19 patients with different levels of laboratory indicators were analysed utilising Kaplan-Meier analysis. RESULTS: 29.8% (190/638) of patients with COVID-19 progressed to severe. Compared with patients with no adverse events, C reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR) and D-dimer were significantly higher in severe patients with adverse events, such as acute myocardial injury, respiratory failure, acute kidney injury, mechanical ventilation, intensive care unit admission, multiple organ dysfunction syndromes and death (all p<0.05). The multivariate logistic analysis suggested that CRP, NLR and D-dimer were independent risk factors for the disease progression of COVID-19 (all p<0.05). The model combining all of them owned the highest area under the receiver operating characteristic curve (AUC) predicting disease progression and death of COVID-19, with AUC of 0.894 (95% CI 0.857 to 0.931) and 0.918 (95% CI 0.873 to 0.962), respectively. Survival analysis suggested that the patients with a high level of CRP, NLR or D-dimer performed shorter overall survival time (all p<0.05). CONCLUSIONS: The combination of CRP, NLR and D-dimer could be an effective predictor for the aggravation and death in patients with COVID-19. The abnormal expression of these indicators might suggest a strong inflammatory response and multiple adverse events in patients with severe COVID-19.
format Online
Article
Text
id pubmed-8488281
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-84882812021-10-04 Clinical value of laboratory indicators for predicting disease progression and death in patients with COVID-19: a retrospective cohort study Wang, Qian Cheng, Jie Shang, Jian Wang, Ying Wan, Jing Yan, You-qin Liu, Wen-bin Zhang, Hai-Ping Wang, Jian-ping Wang, Xiao-yue Li, Zi-ang Lin, Jun BMJ Open Infectious Diseases OBJECTIVES: As early prediction of severe illness and death for patients with coronavirus disease 2019 (COVID-19) is important, we aim to explore the clinical value of laboratory indicators in evaluating the progression and prognosis of patients with COVID-19. DESIGN: Retrospective cohort study. SETTING: Hospital-based study in China. PARTICIPANTS: Adult patients with COVID-19 from December 15, 2019 to March 15, 2020. END POINT: Disease severity and mortality. METHODS: Clinical data of 638 patients with COVID-19 were collected and compared between severe and non-severe groups. The predictive ability of laboratory indicators in disease progression and prognosis of COVID-19 was analysed using the receiver operating characteristic curve. The survival differences of COVID-19 patients with different levels of laboratory indicators were analysed utilising Kaplan-Meier analysis. RESULTS: 29.8% (190/638) of patients with COVID-19 progressed to severe. Compared with patients with no adverse events, C reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR) and D-dimer were significantly higher in severe patients with adverse events, such as acute myocardial injury, respiratory failure, acute kidney injury, mechanical ventilation, intensive care unit admission, multiple organ dysfunction syndromes and death (all p<0.05). The multivariate logistic analysis suggested that CRP, NLR and D-dimer were independent risk factors for the disease progression of COVID-19 (all p<0.05). The model combining all of them owned the highest area under the receiver operating characteristic curve (AUC) predicting disease progression and death of COVID-19, with AUC of 0.894 (95% CI 0.857 to 0.931) and 0.918 (95% CI 0.873 to 0.962), respectively. Survival analysis suggested that the patients with a high level of CRP, NLR or D-dimer performed shorter overall survival time (all p<0.05). CONCLUSIONS: The combination of CRP, NLR and D-dimer could be an effective predictor for the aggravation and death in patients with COVID-19. The abnormal expression of these indicators might suggest a strong inflammatory response and multiple adverse events in patients with severe COVID-19. BMJ Publishing Group 2021-10-01 /pmc/articles/PMC8488281/ /pubmed/34598979 http://dx.doi.org/10.1136/bmjopen-2020-043790 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Infectious Diseases
Wang, Qian
Cheng, Jie
Shang, Jian
Wang, Ying
Wan, Jing
Yan, You-qin
Liu, Wen-bin
Zhang, Hai-Ping
Wang, Jian-ping
Wang, Xiao-yue
Li, Zi-ang
Lin, Jun
Clinical value of laboratory indicators for predicting disease progression and death in patients with COVID-19: a retrospective cohort study
title Clinical value of laboratory indicators for predicting disease progression and death in patients with COVID-19: a retrospective cohort study
title_full Clinical value of laboratory indicators for predicting disease progression and death in patients with COVID-19: a retrospective cohort study
title_fullStr Clinical value of laboratory indicators for predicting disease progression and death in patients with COVID-19: a retrospective cohort study
title_full_unstemmed Clinical value of laboratory indicators for predicting disease progression and death in patients with COVID-19: a retrospective cohort study
title_short Clinical value of laboratory indicators for predicting disease progression and death in patients with COVID-19: a retrospective cohort study
title_sort clinical value of laboratory indicators for predicting disease progression and death in patients with covid-19: a retrospective cohort study
topic Infectious Diseases
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488281/
https://www.ncbi.nlm.nih.gov/pubmed/34598979
http://dx.doi.org/10.1136/bmjopen-2020-043790
work_keys_str_mv AT wangqian clinicalvalueoflaboratoryindicatorsforpredictingdiseaseprogressionanddeathinpatientswithcovid19aretrospectivecohortstudy
AT chengjie clinicalvalueoflaboratoryindicatorsforpredictingdiseaseprogressionanddeathinpatientswithcovid19aretrospectivecohortstudy
AT shangjian clinicalvalueoflaboratoryindicatorsforpredictingdiseaseprogressionanddeathinpatientswithcovid19aretrospectivecohortstudy
AT wangying clinicalvalueoflaboratoryindicatorsforpredictingdiseaseprogressionanddeathinpatientswithcovid19aretrospectivecohortstudy
AT wanjing clinicalvalueoflaboratoryindicatorsforpredictingdiseaseprogressionanddeathinpatientswithcovid19aretrospectivecohortstudy
AT yanyouqin clinicalvalueoflaboratoryindicatorsforpredictingdiseaseprogressionanddeathinpatientswithcovid19aretrospectivecohortstudy
AT liuwenbin clinicalvalueoflaboratoryindicatorsforpredictingdiseaseprogressionanddeathinpatientswithcovid19aretrospectivecohortstudy
AT zhanghaiping clinicalvalueoflaboratoryindicatorsforpredictingdiseaseprogressionanddeathinpatientswithcovid19aretrospectivecohortstudy
AT wangjianping clinicalvalueoflaboratoryindicatorsforpredictingdiseaseprogressionanddeathinpatientswithcovid19aretrospectivecohortstudy
AT wangxiaoyue clinicalvalueoflaboratoryindicatorsforpredictingdiseaseprogressionanddeathinpatientswithcovid19aretrospectivecohortstudy
AT liziang clinicalvalueoflaboratoryindicatorsforpredictingdiseaseprogressionanddeathinpatientswithcovid19aretrospectivecohortstudy
AT linjun clinicalvalueoflaboratoryindicatorsforpredictingdiseaseprogressionanddeathinpatientswithcovid19aretrospectivecohortstudy